Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.65−1.52 (-2.86%)
Close on Nov 17, 2026Market cap $7.18BP/E –Yield –
Cytokinetics total assets
Total assets on the balance sheet at the end of each period.
Cytokinetics's total assets was $1.92B at Jun 30, 2026. For fiscal 2025 it was $1.42B, up 1.6% from the year before. Over ten years it grew 28.6% a year on average. The highest annual figure on record is $1.42B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.42B | +1.6% |
| FY2024 | Dec 31, 2024 | $1.40B | +70.0% |
| FY2023 | Dec 31, 2023 | $824.32M | -18.8% |
| FY2022 | Dec 31, 2022 | $1.01B | +20.6% |
| FY2021 | Dec 31, 2021 | $841.32M | +57.6% |
| FY2020 | Dec 31, 2020 | $533.80M | +84.2% |
| FY2019 | Dec 31, 2019 | $289.81M | +37.2% |
| FY2018 | Dec 31, 2018 | $211.18M | -28.4% |
| FY2017 | Dec 31, 2017 | $294.81M | +73.3% |
| FY2016 | Dec 31, 2016 | $170.14M | +47.6% |
| FY2015 | Dec 31, 2015 | $115.24M | -13.3% |
| FY2014 | Dec 31, 2014 | $132.97M | +59.8% |
| FY2013 | Dec 31, 2013 | $83.19M | +7.3% |
| FY2012 | Dec 31, 2012 | $77.55M | +47.0% |
| FY2011 | Dec 31, 2011 | $52.77M | -32.3% |
| FY2010 | Dec 31, 2010 | $77.99M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.92B | +57.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.27B | +0.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.42B | +1.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.44B | +0.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.23B | -19.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.26B | +56.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.40B | +70.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.44B | +93.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.52B | +95.4% |
| Q1 FY2024 | Mar 31, 2024 | $808.08M | -9.2% |
| Q4 FY2023 | Dec 31, 2023 | $824.32M | -18.8% |
| Q3 FY2023 | Sep 30, 2023 | $740.61M | -31.2% |
| Q2 FY2023 | Jun 30, 2023 | $779.90M | +1.1% |
| Q1 FY2023 | Mar 31, 2023 | $889.82M | +3.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.01B | +20.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.08B | +30.0% |
| Q2 FY2022 | Jun 30, 2022 | $771.72M | +36.8% |
| Q1 FY2022 | Mar 31, 2022 | $856.25M | +48.4% |
| Q4 FY2021 | Dec 31, 2021 | $841.32M | +57.6% |
| Q3 FY2021 | Sep 30, 2021 | $827.54M | +74.5% |
| Q2 FY2021 | Jun 30, 2021 | $564.30M | +142.7% |
| Q1 FY2021 | Mar 31, 2021 | $577.06M | +124.9% |
| Q4 FY2020 | Dec 31, 2020 | $533.80M | +84.2% |
| Q3 FY2020 | Sep 30, 2020 | $474.11M | +153.0% |
| Q2 FY2020 | Jun 30, 2020 | $232.50M | +17.3% |
| Q1 FY2020 | Mar 31, 2020 | $256.58M | +29.2% |
| Q4 FY2019 | Dec 31, 2019 | $289.81M | +37.2% |
| Q3 FY2019 | Sep 30, 2019 | $187.39M | -18.6% |
| Q2 FY2019 | Jun 30, 2019 | $198.22M | -19.8% |
| Q1 FY2019 | Mar 31, 2019 | $198.61M | -29.0% |
| Q4 FY2018 | Dec 31, 2018 | $211.18M | -28.4% |
| Q3 FY2018 | Sep 30, 2018 | $230.28M | -29.4% |
| Q2 FY2018 | Jun 30, 2018 | $247.24M | -27.4% |
| Q1 FY2018 | Mar 31, 2018 | $279.93M | +5.5% |
| Q4 FY2017 | Dec 31, 2017 | $294.81M | +73.3% |
| Q3 FY2017 | Sep 30, 2017 | $326.31M | +106.3% |
| Q2 FY2017 | Jun 30, 2017 | $340.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $265.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $170.14M | – |
| Q3 FY2016 | Sep 30, 2016 | $158.17M | – |
See a number that looks wrong?